IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.

Abstract

Patients with severe alcohol-associated hepatitis (AH) have high mortality. Corticosteroids improve survival only for 30days. We targeted inflammation, cellular injury, and gut leakiness in a randomized clinical trial comparing combination therapy to corticosteroids on 180-day survival. Subjects with a clinical diagnosis of severe AH (Model for End-Stage Liver Disease [MELD] >20, Maddrey discriminant function [MDF] >32) were randomized to receive methylprednisolone (PRED; 28days) or a combination of anakinra (14days) plus pentoxifylline (28days) plus zinc (COMB; 180days). The primary endpoint was survival at 180days. The study was designed in 2013, initiated in October 2014, and completed in March 2018. Five hundred patients were screened to randomize 104subjects with a clinical diagnosis of AH with a MELD score >20. Fifty-three patients were randomized into the COMB and 50 to the PRED treatment; 1 dropped out of the study before randomization. Mean age was 45.3±10.4years; 60.6% were males, 92.3% White, and mean MELD 25.7±3.9. Kaplan-Meier survival estimate at 180 days was 67.9% in COMB and 56% in PRED (HR=0.69; p=0.3001). Survival curves separated by 90days (COMB, 69.8%; PRED, 58.0%; HR=0.69; p=0.28). Survival at 28days was similar between the COMB (83.4%) and PRED groups (81.2%; HR=0.91; p=0.85). There were no unexpected serious adverse events, and incidence of infection was comparable between groups. MELD 20-25 and MELD >26strata showed nonsignificant treatment effects in favor of COMB. A combination of anakinra, pentoxifylline plus zinc provides similar survival benefits compared to corticosteroid therapy in severe AH.